Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of low-molecule heparin in medicament preparation

A low-molecular-weight heparin and drug technology, applied in the application field of low-molecular-weight heparin in pharmaceuticals, can solve the problem that the effect of rheumatoid arthritis has not been reported yet.

Inactive Publication Date: 2010-07-21
上海市长宁区光华中西医结合医院
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the research on low molecular weight heparin is mostly focused on its anticoagulant function, but there is no report on its role in rheumatoid arthritis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of low-molecule heparin in medicament preparation
  • Application of low-molecule heparin in medicament preparation
  • Application of low-molecule heparin in medicament preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1: Experiment of low molecular weight heparin in synovial tissue of rheumatoid arthritis

[0034] Materials and Methods

[0035] 1 Experimental materials

[0036] 1.1 Experimental animals

[0037] Wistar rats, 24, female, 7-8 weeks old, weighing 160-180g, were purchased from the Animal Center of Shanghai Institute of Biological Sciences, and the feeding environment was the SPF animal room of the Department of Experimental Animal Science, Shanghai Jiao Tong University School of Medicine. The rats were free to drink water and After eating, the room temperature is 24±2°C, and the animals are adaptively fed for 3 days before the experiment.

[0038] 1.2 Main reagents

[0039] Modeling reagents: bovine type II collagen, 20mg×4 bottles, purchased from Chondrex, Inc. Company; Freund's complete adjuvant (CFA), American Sigma Company; glacial acetic acid, Beijing Chemical Reagent Company.

[0040] Therapeutic drugs: low molecular weight heparin sodium injection (clex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of low-molecule heparin in preparing medicaments for treating collagen-induced arthritis. The invention provides the application of the low-molecule heparin in preparing the medicaments for treating rheumatic diseases, wherein the rheumatic disease are chronic infectious arthritis. The invention has the advantages of exploring the purpose medical treatment of the low-molecule heparin and developing a new application field. The result indicates that the low-molecule heparin has the function of restraining the synovium inflammation of the chronic infectious arthritis and has one of purposes of restraining the adhesion of synovial fibroblast cells and inflammatory cells. The result provides the experimental basis for seeking biological treating target spots and other small-molecule treating target sports, and the low-molecule heparin has clinical application values.

Description

technical field [0001] The present invention relates to the use of low molecular weight heparin, in particular to the application of low molecular weight heparin in the pharmaceutical field Background technique [0002] Rheumatoid arthritis (rheumatoid arthritis, RA) is a systemic chronic autoimmune disease characterized by joint synovial inflammation, the pathogenesis of RA is still not very clear, Trenthem first found that 50% of RA patients serum There are autoantibodies against type II collagen (Collagentype II, CII), and based on these findings, an experimental arthritis animal model was established for the first time in 1977. CII exists in large quantities in articular cartilage, as well as in the retina and vitreous body. CII is a protein that is isolated from the immune system, but it can be presented as a self-antigen under certain pathological conditions. The humoral and cellular immune responses of collagen, as well as its relationship with the major histocompati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/727A61P19/02A61P29/00
Inventor 肖涟波李宁丽欧阳桂林何勇
Owner 上海市长宁区光华中西医结合医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com